Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited, established in 1781, is a global, patient-focused, and innovation-driven biopharmaceutical company committed to bringing better health and a brighter future to people worldwide.

With a rich history spanning over two centuries, Takeda has evolved into one of the world's leading pharmaceutical companies. It offers a diverse range of products and services across various therapeutic areas.

Therapeutic Areas and Products

Takeda's extensive portfolio addresses several key therapeutic areas including:

• Gastroenterology and Inflammation: Developing treatments for gastrointestinal disorders and inflammatory conditions.
• Rare Diseases: Focusing on therapies for rare and complex conditions.
• Plasma-Derived Therapies: Providing treatments sourced from human plasma.
• Oncology: Offering therapies for various types of cancer.
• Neuroscience: Developing treatments for neurological disorders.
• Vaccines: Providing immunization solutions.

These products are approved by local regulatory agencies in individual countries for specific uses.

Research and Development

Takeda's commitment to innovation is evident in its robust research and development (R&D) efforts. The company operates R&D sites in Japan, the United States, the United Kingdom, and Singapore.

It focuses on areas such as oncology, gastroenterology, rare diseases, neuroscience, and vaccines to drive new medical advancements.

Global Presence

Headquartered in Tokyo, Japan, Takeda has a significant global footprint. In the United States, the company maintains several offices supporting R&D, manufacturing, and commercial operations.

US locations include:

• Houston, TX
• Cicero, IL
• Saint Paul, MN
• Glendale, AZ
• San Marcos, CA
• Lemon Grove, CA
• Kyle, TX
• Las Vegas, NV
• Phoenix, AZ

Recent Developments

In May 2024, Takeda announced a restructuring plan following a drop in annual profit. The plan involves costs of about 140 billion yen ($899 million) aimed at workforce optimization, cost reduction, and technology enhancement.

Additionally, in May 2024, Takeda entered a $2.2 billion deal with Swiss start-up AC Immune to develop an Alzheimer's vaccine. This includes an initial $100 million payment, potential milestone payments totaling $2.1 billion, and royalties above 10% from global sales.

Takeda's dedication to innovation and patient care continues to drive its mission of improving health and well-being worldwide.